Comparison Capricor vs. ANP, page-23

"ANP have maintained that they intend to be supplementary in the DMD therapeutics market rather than as direct competitors to companies like Sarepta, Santhera etc"

@shyaam1996 as a small biotech company you do not want to upset the big players by stating that "our treatment will replace the likes of Sarepta, Santhera etc..." if you are at the late stage development phase then you are looking for big players to inject their money into your treatment.

so it would be unwise to upset these players with unrealistic and inappropriate statements ....once commercialized, the market will then decide how often and when to utilize the ANP treatment.

but as always, if your son had DMD would you want them to use the one with the best results or any of the others....